172
© 2006 The McGraw Hill Companies Pharmacology

© 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Embed Size (px)

Citation preview

Page 1: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

© 2006 The McGraw Hill Companies

Pharmacology

Page 2: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

© 2006 The McGraw Hill Companies

Introduction

Page 3: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Introduction

• Drugs are chemical agents used in the diagnosis, treatment, and prevention of disease

What is pharmacology?

Why is it important?

Page 4: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Introduction

• Written records of drug use date back to the ancient Egyptians

• Hippocrates wrote extensively about drugs

• During his time, a more scientific approach was used in treating specific diseases with drugs

Page 5: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Introduction

• Subspecialties of Pharmacology

–Pharmacokinetics

–Pharmacodynamics

–Pharmacogenetics

–Pharmacogenomics

Page 6: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Introduction

• Pharmacokinetics is dependent upon the body’s ability to move substances within the body– Active transport– Facilitated diffusion– Passive transport

Page 7: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Pharmacology Basics

• Pharmacokinetics considerations– Molecule size and shape– Solubility in water and lipids– Ability to bind to tissue proteins– Ionization

Solubility Exercise

Page 8: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Introduction

• Pharmacodynamics – Study of the

mechanisms by which specific drug dosages act to produce biochemical or physiological changes

Page 9: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Introduction

• Pharmacodynamics – Drugs may act in four different ways:

• Bind to a receptor site• Change the physical properties of the cell• Chemically combine with other chemicals• Alter a normal metabolic pathway

Page 10: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Introduction

• Pharmacogenetics and pharmacogenomics– Study unique genetic processes linked to

DNA coding and genetics

Page 11: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Pharmacogenosy

• The study of natural drug sources– Plants– Animals– Minerals

• What are some common examples of each drug source?

Page 12: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Pharmacogenosy

– Researchers can now manipulate the molecular structure of substances to create synthetic drugs

Page 13: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Plant Sources of Drugs

• Oldest source of medications

• Drugs may consist of using the entire plant, leaves, roots, bulbs, stems, seeds, buds, or blossoms

Page 14: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Animal Sources of Drugs

• Body fluids or glands from animals can act as sources for drugs

• Hormones• Oils and fats• Enzymes

Page 15: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Mineral Sources of Drugs

• Metallic and nonmetallic minerals provide various inorganic materials

• Occur naturally or are combined to form acids, bases, or salts

Page 16: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Introduction

• Laboratory-produced drug sources – New drugs may be a

more pure form of a naturally occurring drug or they may be a synthetic form

Page 17: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Routes

• Routes of Administration– Enteral Route– Parenteral Route– Topical Route

Page 18: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Introduction

• Subroutes of administration– Ingestion– Injection– Absorption– Inhalation

Page 19: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Route of Administration

• Depends of many factors– Accessibility– Rate of absorption– Deactivation by enzymes or acids– Toxicity to tissues

Page 20: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Drug Absorption

• Drug’s progress from its pharmaceutical dosage form to a biologically available substance

• Several factors affect drug absorption

Page 21: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Factors

1. Solubility

2. Concentration

3. pH

4. Site of absorption

5. Blood supply

6. Bioavailability

Page 22: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

RouteOral (PO)

Subcutaneous (SQ)

Topical

Intramuscular (IM)

Rectal (PR)

Sublingual (SL)

Endotracheal (ET)

Inhalation

Intraosseous (IO)

Intavenous (IV)

Rate of AbsorptionSlow

Slow

Moderate

Moderate

Rapid

Rapid

Rapid

Rapid

Immediate

Immediate

Page 23: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Drug Forms

• Usually consist of a powder dissolved in a liquid– Solute: drug– Solvent: liquid in which it is dissolved

• Primary difference between one preparation and another is the solvent

• What is a solution?

Page 24: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Drug Forms

• Liquids

• Solids

• Suppositories

• Inhalants

• Sprays

• Creams/lotions

• Patches

• Lozenges

Page 25: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Liquid Drugs

– Solutions

– Tinctures

– Suspensions

– Spirits

Page 26: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Liquid Drugs

–Emulsions

–Elixirs

–Syrups

Page 27: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Routes of Administration

–Enteral• Orally (PO)

–Parenteral• Intramuscular (IM)

• Subcutaneous (SC or SQ)

• Intravenous (IV)

• Inhalation

Page 28: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Packaging

• Packaging and preparations – Vials

– Ampules

– Self-contained systems or syringes

– Nebules

Page 29: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Solid Drugs

– Administered orally or rectally

• Pills

• Powders

• Capsules

• Tablets

• Suppositories

Page 30: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Inhalants

–Nebulizers

–Metered-dose aerosols

–Turbo inhalers

–Vaporizers

Page 31: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Distribution

• Several factors affect distribution:

• Cardiovascular function

• Regional blood flow

• Drug storage reservoirs

• Physiological barriers

Page 32: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Biotransformation

• Biotransformation has two effects:– It can transform the drug into a more or less

active metabolite– It can make the drug more water soluble (or

less lipid-soluble) to facilitate elimination

Page 33: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Biotransformation

• Can activate metabolites to make the drug active (prodrugs)

• Many processes occur in the liver– First-pass effect– Body detoxifies and disposes of

toxins and excess drug by increasing water solubility

Page 34: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Basics

• Drugs are eliminated in either their original form or as metabolites– Drug excretion is the movement of a drug or

its metabolites from the tissues back into circulation and from secretion into organs of excretion

Page 35: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Elimination

• Can be affected by– Drug half-life– Accumulation– Clearance– Onset, peak, and

duration

Page 36: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Therapeutic Index

• Medication must reach a certain concentration at the target tissue to be effective

• Medication must reach a certain concentration at the target tissue to be effective

Therapeutic index

Therapeutic threshold

Page 37: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Therapeutic Index

• Dose calculation• ED50

• LD50

Page 38: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

© 2006 The McGraw Hill Companies

Receptors

Page 39: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Receptors

• Mechanism of Action: how a drug works– Drug action

– Drug effect

Page 40: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Receptors

• Drug receptors: proteins present on cell membrane to which a drug must bind in order to elicit a desired response

Page 41: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Receptors

• Receptors are classified based on effects – Agonist– Antagonist

• Competitive antagonist• Noncompetitive antagonist

• A drug attached to a receptor site displays affinity

Page 42: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Receptors

• Efficacy: the power of a drug to produce a therapeutic effect– Agonists have affinity and

efficacy– Antagonists have affinity but not

efficacy

• Drug potency: relative amount of drug required to produce the desired response

Page 43: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Receptors

• How do drugs bind to receptor sites?– Ionic bonds– Hydrogen bonds– Hydrophobic bonds– Van der Waals forces– Covalent bonds

Page 44: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Receptors

• Receptor sites– Several drugs may bind to the same receptor

site, thus creating different responses by the cells

– Two main functions• Ligand binding• Message propagation

Page 45: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

© 2006 The McGraw Hill Companies

Neurotransmitters

Page 46: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Neurotransmitters

• The nervous system is the body’s control system, regulating all bodily function via electrical impulses

• What are the two main parts of the central nervous system that drugs can affect?

Page 47: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Neurotransmitters

• Two divisions:– Central Nervous System (CNS)– Peripheral Nervous System (PNS)

Page 48: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Neurotransmitters

Page 49: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

NeurotransmittersOrgan Sympathetic stimulation Parasympathetic stimulation

Heart Increased rate, force

Decreased rate, force

Lungs Bronchodilation Bronchoconstriction

Kidneys Decreased output None

Systemic blood vessels

Constricted – dilated –

None

Liver Glucose release Glycogen synthesis

Blood glucose Increased None

Pupils Dilated Constricted

Basal metabolism Increased up to 100%

None

Skeletal muscle Increased strength None

Page 50: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Neurotransmitters

• Nerves of the autonomic nervous system exit the CNS and enter autonomic ganglia

Page 51: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Neurotransmitters

• No connection exists between two nerve cells or a nerve cell and its target organ; instead there is a space called a synapse

• Neurotransmitters are specialized chemicals that conduct impulses between nerve cells or between a nerve cell and an organ

Page 52: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Neurotransmitters

• Neurotransmitters of ANS:– Acetylcholine (Ach)– Norepinephrine (NE)

• Synapses:– Cholinergic synapses: use acetylcholine– Adrenergic synapses: use norepinephrine

Page 53: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Neurotransmitters

• What is the action of an adrenergic drugs?

• What is the action of a cholinergic drug?

Page 54: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Neurotransmitters

• Sympathetic Nervous System– Arises from the thoracic and lumbar

regions of the spinal cord– Results in direct stimulation of adrenal

medulla and release of norepinephrine (noradrenaline) and epinephrine (adrenaline)

Page 55: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Neurotransmitters

• Sympathetic Nervous System– Stimulation ultimately results in release of

norepinephrine from postganglionic nerves– Sympathetic stimulation also results in

release of epinephrine and norepinephrine from the adrenal medulla

– What is/are the chemical mediators of the SNS?

Page 56: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Neurotransmitters

• Types of sympathetic receptors– What is the action of adrenergic receptors?

• Alpha1 (1)

• Alpha2 (2)

• Beta1 (1)

• Beta2 (2)

– Of dopaminergic receptors?

Page 57: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

NeurotransmittersReceptor Actions

alpha1 (1) Peripheral vasoconstriction, increased contractile force, decreased rate

alpha2 (2) Peripheral vasoconstriction

beta1 (1) Increased heart rate, contractile force and automaticity

beta2 (2) Peripheral vasodilation, bronchodilation, uterine smooth muscle relaxation

dopaminergic Renal vasodilation and mesenteric vasodilation

Page 58: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Neurotransmitters

• Sympathomimetics: medications that stimulate the sympathetic nervous system

• Sympatholytics: medications that inhibit the sympathetic nervous system

Page 59: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Neurotransmitters

• The Parasympathetic Nervous System– Arises from the brain stem and sacral

segments of the spinal cord– Synapse in parasympathetic ganglia

– What is/are the chemical mediators of the PNS?

Page 60: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Neurotransmitters

• Stimulation of the parasympathetic nervous system results in:– Pupillary constriction

– Secretion by digestive glands

– Increased smooth muscle activity along GI tract

– Bronchoconstriction

– Reduction in heart rate and contractile force

Page 61: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Neurotransmitters

• Parasympatholytics: medications that block the actions of the parasympathetic nervous system

• Parasympathomimetics: medications that stimulate the parasympathetic nervous system

Page 62: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

© 2006 The McGraw Hill Companies

Homeostasis and Balance

Page 63: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Homeostasis and Balance

• Our bodies require constant regulation in order to maintain balance and control

Page 64: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

© 2006 The McGraw Hill Companies

Drug Names and

References

Page 65: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Drug Names and References

• Drug Classification– Prescription (Rx)

– Over-the-counter (OTC)• Herbal

Page 66: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Drug Names and References

• Drug Names– Official: generally same as generic name

• meperidine hydrochloride, USP

– Chemical: anatomic and molecular structure• Ethyl 1-methyl-4-phenylisonipecotate

hydrochloride

Page 67: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Drug Names and References

• Drug Names– Generic: abbreviated version of chemical

name• meperidine hydrochloride

– Trade: name based on chemical name or problem used to treat

• Demerol hydrochloride• What is another term for a drug’s trade name?

Page 68: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Sources of Drug Information

• Using multiple sources may provide the best information

• United States Pharmacopia (USP)• National Formulary (NF)• American Hospital Formulary Service• Physician’s Desk Reference (PDR)• Packaging inserts, as required by law

Page 69: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Drug Names and References

• A process must be approved by the FDA

• Studies take place in four phases– Preclinical testing, research, and development– Clinical research and development– NDA Review– Postmarketing surveillance

Page 70: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Drug Names and References

• Bringing a drug to market is a process that takes several years and must be approved by the U.S. Food and Drug Administration (FDA)

Page 71: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Drug Names and References

• Studies take place in four phases– Preclinical testing, research and development– Clinical research and development– NDA Review– Postmarketing surveillance

Page 72: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Drug Names and References

• New Drug Development

–Phase I

–Phase II

–Phase III

–Phase IV

Page 73: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Drug Names and References

• New Drug Development – Orphan Drugs

• Drugs not developed or adopted

Page 74: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Unlabeled Uses of Drugs

• FDA only accepts a new drug for the indications in which phase II and III clinical studies have shown it to be effective.

• Indications approved (labeled)• Not approved (unlabeled)

Page 75: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Drug Names and References

• Unlabeled uses of drugs– FDA recognizes that a drug’s labeling does

not always contain the most current information on usage

Page 76: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

© 2006 The McGraw Hill Companies

Patient Medication Rights

Page 77: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Patient Medication Rights

• What are the six “rights” of patient medication administration that ensure safe, proper, and effective administration?

Page 78: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Patient Medication Rights

1. Right patient

2. Right medication

3. Right dose

4. Right route

5. Right time

6. Right documentation

Page 79: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

© 2006 The McGraw Hill Companies

Classifying Medications

Page 80: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

AHA Classes of Recommendations for Drug Therapies

• Class I

Benefit >>> Risk

– Procedure/treatment or diagnostic test/assessment should be performed/administered

Table 15-7

Page 81: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

AHA Classes of Recommendations for Drug Therapies

• Class IIaBenefit >>RiskIt is reasonable to perform procedure/administer treatment or perform diagnostic test/assessment.

Table 15-7

Page 82: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

AHA Classes of Recommendations for Drug Therapies

• Class IIbBenefit RiskProcedure/treatment or diagnostic test/assessment may be considered.

Table 15-7

Page 83: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

AHA Classes of Recommendations for Drug Therapies

• Class IIIRisk Benefit Procedure/treatment or diagnostic test/assessment should not be performed/administered. It is not helpful and may be harmful.

Table 15-7

Page 84: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

AHA Classes of Recommendations for Drug Therapies

• Class Indeterminate– Research is just getting started– Continuing area of research– No recommendation until further research

(e.g., cannot recommend for or against)

Table 15-7

Page 85: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Classifying Medications

• Classified with other similar medications with the same effects– Body system/disease used to treat– Chemical group– Receptor binding site

Page 86: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

© 2006 The McGraw Hill Companies

What Paramedics Need to Know About Drugs

Page 87: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

What Paramedics Need to Know About Drugs

• Comprehensive drug list based on protocol– Be familiar with AHA Guidelines for

treating cardiac patients– Know local protocol and drugs used in

your region

Page 88: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Need to Know

• Components of a drug

profile

– Names

– Classification

– Mechanism of action

– Indications

– Pharmacokinetics

Page 89: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

What Paramedics Need to Know About Drugs

• Components of a drug profile– Side effects/adverse reactions

– Contraindications

– Dosage

– How supplied

– Special considerations

Page 90: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Need to Know

• Special considerations in drug therapy– Pediatric patients– Geriatric patients– Pregnant and lactating

patients

Page 91: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Need to Know

• Use care administering medications

• Follow the medication order

Page 92: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

What Paramedics Need to Know About Drugs

• Preparation involves selecting the appropriate sized needle and syringe

• No compensation for dead space is necessary when drawing up medications

Page 93: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

What Paramedics Need to Know About Drugs

• Use different needles when reconstituting medication to be drawn up

• Use caution when mixing drugs in one syringe

• ALWAYS use sterile technique

Page 94: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Need to Know

• Medical control– As a paramedic, you operate under the

licensure of a medical director who is responsible for all of your actions

– The medical director determines which drugs you will administer and the routes by which they are given

Page 95: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Need to Know

• Reduce the potential for contamination

• Identify allergies prior to contacting hospital

• Obtain vital signs

• Obtain and confirm/repeat order

• Write the order and the time

Page 96: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Need to Know

• Select the proper medication

• Inspect the medication

• Confirm the order and medication

• Six rights of administration

• Record drug, dose, volume, route, and time, and obtain vital signs and effects

Page 97: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

What Paramedics Need to Know About Drugs

• Storage and handling considerations– USP28-NF23, PF30 (6), p. 2118

• “Storage of Drugs in Emergency Medical Services (EMS) Vehicles”

• Narcotics and controlled substances should be secured according to local protocols

Page 98: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

What Paramedics Need to Know About Drugs

• Legal regulations, standards, and legislation– International controls

• United Nations World Health Organization provides technical assistance and encourages new research for drug use

Page 99: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Need to Know

• Legal regulations, standards, and legislation– Controls in the U.S.

• Testing (animals studies and clinical patient trials)

• Legislative control

Page 100: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Need to Know

• Legal regulations, standards, and legislation– “Truth in labeling”

• Why might “truth in labeling” be important?

Page 101: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Need to Know

• Legal regulations, standards, and legislation– Narcotics

• Harrison Narcotic Act, 1914• Comprehensive Drug Abuse Prevention and Control

Act, 1970

Page 102: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Schedule of Controlled DrugsCategory Examples

Schedule INo recognized medical use;

high abuse potential

Opiates (heroin), hallucinogens (LSD), depressants (methaqualone)

Schedule IIWritten prescriptions required;

no telephone renewals

Opiates (codeine, morphine, meperidine), stimulants (amphetamines), depressants

Schedule IIIPrescriptions rewritten after six months or five refills

Opiates (codeine <1.8 g/dl), stimulants, depressants, anabolic steroids

Schedule IVPrescriptions rewritten after six months or five refills

Opiates (propoxyphene), stimulants, depressants (chloral hydrate)

Schedule VAny nonnarcotic medication, OTC

Small amounts of opiates when uses as antitussives or antidiarrheals

Page 103: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Need to Know

• Legal regulations, standards, and legislation– Controlled Substances Act, 1970

Page 104: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Need to Know

• Legal regulations, standards, and legislation– Canadian drug legislation

• Under direct control of Department of National Health and Welfare

• Food and Drug Act, 1941• Canadian Food and Drugs Act, 1953

Page 105: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Need to Know

• Legal regulations, standards, and legislation– Canadian Narcotic Control Act and Regulations

• Canadian Narcotic Control Act, 1965– Restricts sale, possession, and use of narcotics– Restricts narcotic distribution to authorized personnel

Page 106: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Need to Know

• Legal regulations, standards, and legislation– Drug Standards

• United States Pharmacopeia (USP) is official standard to maintain uniformity

Page 107: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Need to Know

• Important pharmacological terminology

– What is antagonism?

– What is cumulative action?

– What is potentiation?

– What is synergism?

Page 108: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Need to Know

• Important pharmacological terminology

– Contraindications

– Hypersensitivity

– Idiosyncrasy

– Side effects

– Untoward effects

Page 109: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Need to Know

• Important pharmacological terminology

– Bolus

– Indication

– Therapeutic action

– Tolerance

Page 110: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Need to Know

• Important pharmacological terminology

– Depressant

– Habituation

– Refractory

– Stimulant

Page 111: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

© 2006 The McGraw Hill Companies

Pre- and Postmedication Administration

Procedures

Page 112: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Pre- and Postmedication Administration Procedures

• Premedication procedures– Obtain a complete SAMPLE history– Obtain a full set of vital signs– Complete a detailed exam– Contact medical control for authorization

Page 113: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Pre- and Postmedication Administration Procedures

• Postmedication procedures– Document– Obtain a full set of vital signs– Complete a detailed exam– Ongoing assessment

Page 114: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Summary

• In order to deliver exceptional patient care, the paramedic must have a basic understanding of the responsibilities and scope of management prior to administration of any drug

Page 115: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

© 2006 The McGraw Hill Companies

Classifications

Page 116: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Street Secret

• Most drugs within the same class have the same suffix; this name generally only applies to the generic name– Beta blockers: –olol– Antihyperlipidemics: –statin– ACE inhibitors: –pril– Calcium channel blocker: –ipines– Opiods: –ine, –one

Page 117: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Street Secret

• Shortcut for remembering what types of doses cardiac drugs have (works for all ACLS drugs)– If the drug begins with a consonant, it is a

two-part dose for normal administration:• Lidocaine—mg/kg• Cardizem—mg/kg• Procainamide—mg/min

Page 118: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Street Secret

• Shortcut for remembering what types of doses cardiac drugs have (works for all ACLS drugs)– If the drug begins with a vowel, it is a one-part

dose:• Epinephrine—mg• Adenosine—mg• Atropine—mg

– Note: This does not work for drips

Page 119: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Street Secret

• A key to remembering the doses on ACLS drugs is as easy as taking a pulse– The dose for a patient with a pulse is half that

of a patient without a pulse

Page 120: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

• Antiarrhythmics• Adenosine

• Amiodarone

• Lidocaine

• Procainamide

ACLS Medications

Page 121: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

• Catecholamine-sympathomimetic

• Epinephrine 1:10,000

• Isoproterenol

ACLS Medications

Page 122: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

• Inotrope• Digoxin

• Epinephrine 1:10,000

ACLS Medications

Page 123: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

• Vasopressors• Dopamine

• Dobutamine

• Epinephrine 1:1 000

• Norepinephrine

• Vasopressin

ACLS Medications

Page 124: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

• Calcium channel blockers

• Diltiazem

• Verapamil

ACLS Medications

Page 125: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

• Parasympatholytics• Atropine

ACLS Medications

Page 126: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

• Mineral/electrolyte• Calcium chloride

• Magnesium sulfate

• Sodium bicarbonate

ACLS Medications

Page 127: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

• Endocrine/metabolic enhancing agent

• Vasopressin

ACLS Medications

Page 128: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Classifying Medications

• Analgesics–Nonsteroidal anti-inflammatory

agents (NSAID)• Ibuprofen

• Ketorolac

Page 129: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Classifying Medications

• Analgesics–Narcotics

• Butorphanol

• Fentanyl

• Meperdine

• Morphine sulfate

• Nalbuphine

Page 130: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Classifying Medications

• Analgesics–Other analgesics

• Acetaminophen

Page 131: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Classifying Medications

• Anaphylaxis–Antianaphylactic agents

• Epinephrine 1:1 000

• Diphenhydramine

• Hydroxyzine

Page 132: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Classifying Medications

• Anesthetics– Topical anesthetics

• Benzocaine• Cetacaine• Lidocaine topical gel• Procaine• Proparacaine• Tetracaine

Page 133: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Classifying Medications

• Anesthetics–Local anesthetics

• Procaine

• Proparacaine

• Tetracaine

Page 134: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Classifying Medications

• Anesthetics–Inhaled agents

• Nitrous oxide

Page 135: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Classifying Medications

• Antianginal agents–Nitroglycerine

–Nitroprusside

Page 136: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Classifying Medications

• Anticoagulants– Heparin– Warfarin sodium

Page 137: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Classifying Medications

• Anticonvulsants–Anticonvulsants

• Fosphenytoin

• Phenobarbital

• Phenytoin

Page 138: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Classifying Medications

• Anticonvulsants–Benzodiazepine

• Diazepam

• Lorazepam

• Midazolam

Page 139: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Classifying Medications

• Antiemetics–Droperidol

–Prochlorperazine

–Promethazine–Hydroxyzine

Page 140: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Classifying Medications

• Antihypertensives–Antihypertensive

• Clonidine

• Diazoxide

Page 141: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Classifying Medications

• Antihypertensives–ACE Inhibitor (acetylcholinesterase)

• Enalapril

Page 142: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Classifying Medications

• Antihypertensives–Calcium channel blocker

• Nifedipine

Page 143: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Classifying Medications

• Antihypertensives–Vasodilator

• Nitroprusside

Page 144: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Classifying Medications

• Antihypoglycemics–Dextrose

–Glucagon

–Insulin

–Oral glucose paste

Page 145: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Classifying Medications

• Antiplatelet agents–Acetylsalicylic

acid (ASA) or aspirin

Page 146: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Classifying Medications

• Antitoxicologics–Anticholinergic

• Atropine

Page 147: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Classifying Medications

• Antitoxicologics–Antidote

• Cyanide antidote kit

• Methylene blue

• Physostigmine

• Pralidoxime auto injector

Page 148: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Classifying Medications

• Beta blockers–Esmolol

–Labetalol

–Metoprolol

–Propranolol

Page 149: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Classifying Medications

• Diuretics–Diuretic

• Mannitol

Page 150: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Classifying Medications

• Diuretics–Loop diuretics

• Bumetanide

• Furosemide

Page 151: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Classifying Medications

• Fibrinolytics– Alteplase

– Antithrombin III

– Heparin

– Reteplase

– Tenectplase

– Urokinase

Page 152: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Classifying Medications

• Gastric decontaminants– Toxicological agents

• Activated charcoal• Ipecac

Page 153: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Classifying Medications

• Induction agents–Analgesic

• Ketamine

Page 154: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Classifying Medications

• Induction agents–Barbiturate

• Methohexital

• Thiopental

Page 155: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Classifying Medications

• Induction agents–Benzodiazepine

• Midazolam

Page 156: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Classifying Medications

• Induction agents–Hypnotic

• Etomidate

Page 157: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Classifying Medications

• Induction agents–Opiate

• Fentanyl

Page 158: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Classifying Medications

• Narcotic and benzodiazepine antagonists–Flumazenil

–Naloxone

–Nalmefene

Page 159: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Classifying Medications

• Nasal decongestants– Oxymetazoline

nasal – Phenylephrine

nasal

Page 160: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Classifying Medications

• Neuroleptics–Antipsychotics

• Chlorpromazine

• Haloperidol

Page 161: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Classifying Medications

• Neuroleptics–Antiemetic

• Droperidol

Page 162: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Classifying Medications

• Paralytics– Neuromuscular blocking agents (NMBA)

• Depolarizing– Succinylcholine

• Nondepolarizing– Mivacurium– Pancuronium– Vecuronium

Page 163: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Classifying Medications

• Postpartum agents–Oxytocin

Page 164: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Classifying Medications

• Respiratory agents–Bronchodilators

• Sympathomimetic (adrenergic)– Beta2 selective

» Albuterol» Isoetharine» Terbutaline

Page 165: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Classifying Medications

• Respiratory agents–Bronchodilators

• Sympathomimetic (adrenergic)– Nonselective

» Epinephrine » Epinephrine (inhaled)» EpiPen Autoinjector/EpiPen Jr» Metaproterenol» Racemic epinephrine

Page 166: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Classifying Medications

• Respiratory agents–Bronchodilators

• Combination agents– Albuterol/ipratoprium

combination

Page 167: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Classifying Medications

• Respiratory agents–Bronchodilators

• Methylxanthine (xanthine) derivative– Aminophylline

Page 168: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Classifying Medications

• Respiratory agents– Bronchodilators

• Parasympatholytic (anticholinergic)

– Ipratoprium

Page 169: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Classifying Medications

• Steroids–Dexamethasone

–Hydrocortisone

–Prednisone

–Methylprednisolone sodium succinate

Page 170: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Classifying Medications

• Tocolytics–Magnesium sulfate

–Terbutaline

Page 171: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Classifying Medications

• Vasopressors–Adrenergics

–Sympathomimetics

–Catecholamines

Page 172: © 2006 The McGraw Hill Companies Pharmacology. © 2006 The McGraw Hill Companies Introduction

Classifying Medications

• Vitamins and electrolytes– Calcium chloride

– Calcium gluconate

– Magnesium sulfate

– Potassium chloride

– Sodium bicarbonate

– Thiamine